| Title |
Feasibility and acceptance of simultaneous amyloid PET/MRI
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, July 2016
|
| DOI | 10.1007/s00259-016-3462-x |
| Pubmed ID | |
| Authors |
Lisa Schütz, Donald Lobsien, Dominik Fritzsch, Solveig Tiepolt, Peter Werner, Matthias L. Schroeter, Jörg Berrouschot, Dorothee Saur, Swen Hesse, Thies Jochimsen, Michael Rullmann, Bernhard Sattler, Marianne Patt, Hermann-Josef Gertz, Arno Villringer, Joseph Claßen, Karl-Titus Hoffmann, Osama Sabri, Henryk Barthel |
| Abstract |
Established Alzheimer's disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging (PET/MRI) offers the chance to obtain both biomarker category read-outs within one imaging session, with increased patient as well as referrer convenience. The aim of this pilot study was to investigate this matter for the first time. 100 subjects (age 70 ± 10 yrs, 46 female), n = 51 with clinically defined mild cognitive impairment (MCI), n = 44 with possible/probable AD dementia, and n = 5 with frontotemporal lobe degeneration, underwent simultaneous [(18)F]florbetaben or [(11)C]PIB PET/MRI (3 Tesla Siemens mMR). Brain amyloid load, mesial temporal lobe atrophy (MTLA) by means of the Scheltens scale, and other morphological brain pathologies were scored by respective experts. The patients/caregivers as well as the referrers were asked to assess on a five-point scale the convenience related to the one-stop-shop PET and MRI approach. In three subjects, MRI revealed temporal lobe abnormalities other than MTLA. According to the National Institute on Aging-Alzheimer's Association classification, the combined amyloid-beta PET/MRI evaluation resulted in 31 %, 45 %, and 24 % of the MCI subjects being categorized as "MCI-unlikely due to AD", "MCI due to AD-intermediate likelihood", and "MCI due to AD-high likelihood", respectively. 50 % of the probable AD dementia patients were categorized as "High level of evidence of AD pathophysiological process", and 56 % of the possible AD dementia patients as "Possible AD dementia - with evidence of AD pathophysiological process". With regard to the International Working Group 2 classification, 36 subjects had both positive diagnostic and progression biomarkers. The patient/caregiver survey revealed a gain of convenience in 88 % of responders as compared to a theoretically separate PET and MR imaging. In the referrer survey, an influence of the combined amyloid-beta PET/MRI on the final diagnosis was reported by 82 % of responders, with a referrer acceptance score of 3.7 ± 1.0 on a 5-point scale. Simultaneous amyloid PET/MRI is feasible and provides imaging biomarkers of all categories which are able to supplement the clinical diagnosis of MCI due to AD and that of AD dementia. Further, patient and referrer convenience is improved by this one-stop-shop imaging approach. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 1% |
| Unknown | 76 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 12% |
| Other | 8 | 10% |
| Student > Master | 8 | 10% |
| Student > Doctoral Student | 8 | 10% |
| Student > Bachelor | 5 | 6% |
| Other | 19 | 25% |
| Unknown | 20 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 31% |
| Psychology | 7 | 9% |
| Neuroscience | 6 | 8% |
| Nursing and Health Professions | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 12 | 16% |
| Unknown | 22 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2016.
All research outputs
#2,757,086
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#221
of 3,083 outputs
Outputs of similar age
#50,777
of 366,829 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#3
of 46 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 366,829 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.